Neurogene (NASDAQ:NGNE) Posts Quarterly Earnings Results, Misses Estimates By $0.09 EPS

Neurogene (NASDAQ:NGNE) announced its quarterly earnings data on Tuesday. The company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.30) by ($0.09), Zacks reports.

Neurogene Stock Up 2.1%

Neurogene stock traded up $0.65 during trading on Tuesday, reaching $31.54. The stock had a trading volume of 103,482 shares, compared to its average volume of 167,081. Neurogene has a 52-week low of $14.65 and a 52-week high of $37.27. The stock has a market cap of $492.65 million, a PE ratio of -7.44 and a beta of 1.69. The business has a 50 day moving average price of $23.48 and a 200 day moving average price of $22.06.

Analyst Ratings Changes

A number of research firms have issued reports on NGNE. Canaccord Genuity Group reduced their target price on shares of Neurogene to $180.00 and set a “buy” rating on the stock in a report on Monday, April 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neurogene in a research report on Tuesday, April 21st. Lifesci Capital initiated coverage on Neurogene in a research note on Monday, January 26th. They issued an “outperform” rating and a $50.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $70.00 target price on shares of Neurogene in a report on Tuesday, January 13th. Finally, Guggenheim assumed coverage on Neurogene in a research note on Tuesday, April 28th. They set a “buy” rating and a $69.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $67.00.

Insider Buying and Selling

In other news, insider Stuart Cobb sold 6,797 shares of Neurogene stock in a transaction on Friday, March 13th. The shares were sold at an average price of $20.81, for a total transaction of $141,445.57. Following the completion of the sale, the insider directly owned 30,497 shares of the company’s stock, valued at approximately $634,642.57. The trade was a 18.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Christine Mikail Cvijic sold 9,600 shares of Neurogene stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $31.25, for a total transaction of $300,000.00. Following the sale, the chief financial officer directly owned 93,640 shares of the company’s stock, valued at approximately $2,926,250. This trade represents a 9.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 20,442 shares of company stock worth $525,622. Insiders own 9.92% of the company’s stock.

Institutional Investors Weigh In On Neurogene

Institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets lifted its position in shares of Neurogene by 89.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock worth $36,000 after purchasing an additional 978 shares during the last quarter. Daiwa Securities Group Inc. purchased a new stake in shares of Neurogene during the 4th quarter worth $66,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Neurogene by 17.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock worth $82,000 after purchasing an additional 1,059 shares during the last quarter. Bridgeway Capital Management LLC purchased a new stake in shares of Neurogene during the 3rd quarter worth $187,000. Finally, Wells Fargo & Company MN lifted its position in shares of Neurogene by 45.2% during the 4th quarter. Wells Fargo & Company MN now owns 11,037 shares of the company’s stock worth $227,000 after purchasing an additional 3,438 shares during the last quarter. 52.37% of the stock is owned by hedge funds and other institutional investors.

Neurogene Company Profile

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.